End-of-day quote
Korea S.E.
03:30:00 14/05/2024 am IST
|
5-day change
|
1st Jan Change
|
3,295
KRW
|
+0.15%
|
|
-6.79%
|
+6.63%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,50,365
|
1,91,246
|
2,19,226
|
3,27,966
|
2,42,875
|
Enterprise Value (EV)
1 |
1,41,036
|
1,83,843
|
2,25,137
|
3,22,542
|
2,33,135
|
P/E ratio
|
33.1
x
|
23.2
x
|
22.7
x
|
-108
x
|
-1,445
x
|
Yield
|
-
|
0.6%
|
0.7%
|
-
|
-
|
Capitalization / Revenue
|
3.27
x
|
3.27
x
|
3.4
x
|
3.8
x
|
4.6
x
|
EV / Revenue
|
3.06
x
|
3.14
x
|
3.5
x
|
3.74
x
|
4.41
x
|
EV / EBITDA
|
19.3
x
|
20.2
x
|
18.7
x
|
34.3
x
|
102
x
|
EV / FCF
|
-100
x
|
73.7
x
|
-14.1
x
|
247
x
|
-397
x
|
FCF Yield
|
-1%
|
1.36%
|
-7.12%
|
0.41%
|
-0.25%
|
Price to Book
|
3.59
x
|
3.57
x
|
3.39
x
|
4.8
x
|
2.38
x
|
Nbr of stocks (in thousands)
|
65,853
|
68,574
|
68,867
|
70,530
|
78,600
|
Reference price
2 |
2,283
|
2,789
|
3,183
|
4,650
|
3,090
|
Announcement Date
|
19/03/20
|
22/03/21
|
22/03/22
|
22/03/23
|
19/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
46,040
|
58,520
|
64,403
|
86,277
|
52,814
|
EBITDA
1 |
7,303
|
9,095
|
12,033
|
9,412
|
2,290
|
EBIT
1 |
5,873
|
7,040
|
9,007
|
5,309
|
-1,186
|
Operating Margin
|
12.76%
|
12.03%
|
13.99%
|
6.15%
|
-2.25%
|
Earnings before Tax (EBT)
1 |
5,375
|
9,471
|
12,827
|
-2,345
|
325.7
|
Net income
1 |
4,195
|
8,302
|
11,031
|
-2,995
|
-164
|
Net margin
|
9.11%
|
14.19%
|
17.13%
|
-3.47%
|
-0.31%
|
EPS
2 |
69.00
|
120.2
|
140.1
|
-43.00
|
-2.138
|
Free Cash Flow
1 |
-1,410
|
2,495
|
-16,022
|
1,307
|
-586.8
|
FCF margin
|
-3.06%
|
4.26%
|
-24.88%
|
1.51%
|
-1.11%
|
FCF Conversion (EBITDA)
|
-
|
27.44%
|
-
|
13.88%
|
-
|
FCF Conversion (Net income)
|
-
|
30.06%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
16.67
|
22.22
|
-
|
-
|
Announcement Date
|
19/03/20
|
22/03/21
|
22/03/22
|
22/03/23
|
19/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
5,911
|
-
|
-
|
Net Cash position
1 |
9,329
|
7,404
|
-
|
5,424
|
9,740
|
Leverage (Debt/EBITDA)
|
-
|
-
|
0.4912
x
|
-
|
-
|
Free Cash Flow
1 |
-1,410
|
2,495
|
-16,022
|
1,307
|
-587
|
ROE (net income / shareholders' equity)
|
13.8%
|
17.3%
|
19%
|
-4.2%
|
-0.06%
|
ROA (Net income/ Total Assets)
|
6.97%
|
6.48%
|
6.67%
|
2.51%
|
-0.43%
|
Assets
1 |
60,162
|
1,28,066
|
1,65,420
|
-1,19,519
|
38,053
|
Book Value Per Share
2 |
636.0
|
782.0
|
938.0
|
968.0
|
1,300
|
Cash Flow per Share
2 |
79.00
|
117.0
|
89.40
|
211.0
|
881.0
|
Capex
1 |
5,547
|
3,947
|
19,598
|
4,894
|
4,002
|
Capex / Sales
|
12.05%
|
6.75%
|
30.43%
|
5.67%
|
7.58%
|
Announcement Date
|
19/03/20
|
22/03/21
|
22/03/22
|
22/03/23
|
19/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +6.63% | 21Cr | | -29.13% | 984.28Cr | | -1.61% | 315.1Cr | | +31.06% | 298.86Cr | | -14.73% | 215.05Cr | | -13.60% | 180.04Cr | | +71.76% | 148.77Cr | | +20.67% | 77Cr | | -2.18% | 76Cr | | -23.88% | 57Cr |
Bio Diagnostics & Testing
|